Cetuximab in Treating Patients With Stage IV Colorectal Cancer

Summary

RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of cetuximab in treating patients who have stage IV colorectal cancer that has not responded to previous treatment.

Timeline

Start

2001-03

Primary completion

2002-08

Completion

—

Drugs

Indications